

Fc gamma RIII/CD16

Catalog # PVGS1911

Product Information

Primary Accession Species	Q8SPW2-1 Cynomolgus
Sequence	Gly17-Gln208
Purity	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin Level	Less than 1EU per μ g by the LAL method.
Biological Activity	Rituximab captured on CM5 Chip via Protein A can bind Fc gamma RIII/CD16, His, Cynomolgus in SPR assay (Biacore T200). Test result was comparable to standard batch.
Expression System	HEK293
Theoretical Molecular Weight	23.1 kDa
Formulation Reconstitution	Lyophilized from a 0.22 μ m filtered solution in PBS, (pH 7.4). Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μ g/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Additional Information

Target Background	Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human Fc gamma RI, Fc gamma RIIA, Fc gamma RIIB, Fc gamma RIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all Fc gamma R; Fc gamma RII and Fc gamma RIII also utilize residues outside this common set.
--------------------------	---

Protein Information

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.